10-Q: 23andMe Reports Q3 2024 Results, Faces Goodwill Impairment and Nasdaq Compliance Issues

23andMe's Q3 2024 results reveal a significant net loss, driven by a goodwill impairment charge and decreased revenue, alongside ongoing efforts to address a cyber security incident and Nasdaq listing compliance.

Summary

• 23andMe reported a net loss of $278 million for the three months ended December 31, 2023, and a net loss of $457.9 million for the nine months ended December 31, 2023.
• The company's revenue decreased by 33% to $44.7 million for the quarter and 25% to $155.6 million for the nine months, compared to the same periods in the previous year.
• The decrease in revenue was primarily due to lower sales of PGS kits and a reduction in research service revenue following the conclusion of the GSK agreement.
• A significant goodwill impairment charge of $198.8 million was recorded during the quarter, contributing to the substantial net loss.
• The company is also addressing a cyber security incident that occurred in October 2023, incurring $2.7 million in expenses, offset by $1.7 million in insurance recoveries.
• 23andMe received a Nasdaq deficiency letter for not maintaining a minimum bid price of $1 per share and has 180 days to regain compliance.
• The company's cash and cash equivalents stood at $242.4 million as of December 31, 2023.
• The company believes its cash and cash equivalents will be sufficient to fund estimated operating expenses and capital expenditure requirements for at least 12 months from the date of the issuance of these condensed consolidated financial statements.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant losses, a large goodwill impairment, and a Nasdaq compliance issue. While there are some positive aspects, such as cost reductions, the overall tone is negative from an investment perspective.

Positives

• The company's research and development expenses decreased by 27% for the quarter and 2% for the nine months ended December 31, 2023.
• The company's sales and marketing expenses decreased by 31% for the quarter and 30% for the nine months ended December 31, 2023.
• The company believes its cash and cash equivalents will be sufficient to fund estimated operating expenses and capital expenditure requirements for at least 12 months from the date of the issuance of these condensed consolidated financial statements.

Negatives

• The company's revenue decreased by 33% for the quarter and 25% for the nine months ended December 31, 2023.
• The company recorded a $198.8 million goodwill impairment charge in Q3 2024.
• The company's net loss for the quarter was $278 million and $457.9 million for the nine months ended December 31, 2023.
• The company received a Nasdaq deficiency letter for not maintaining a minimum bid price of $1 per share.
• The company is addressing a cyber security incident that occurred in October 2023, incurring $2.7 million in expenses, offset by $1.7 million in insurance recoveries.

Risks

• The company faces the risk of delisting from the Nasdaq Stock Market if it fails to regain compliance with the minimum bid price requirement.
• The cyber security incident could lead to further financial losses, reputational damage, and legal liabilities.
• The company's ability to generate revenue from its therapeutic product candidates depends on successful clinical trials and regulatory approvals.
• The company's ability to attract new customers and retain existing subscribers is crucial for future growth.
• The company's reliance on a few key suppliers for raw materials and laboratory services poses a concentration risk.
• The company's ability to enter into new collaboration agreements will affect its research services revenues.

Future Outlook

The company expects to continue to incur operating losses and negative cash flows from operations for the foreseeable future due to investments in research and development, and operating expenses. The company believes its cash and cash equivalents will be sufficient to fund estimated operating expenses and capital expenditure requirements for at least 12 months from the date of the issuance of these condensed consolidated financial statements.

Management Comments

• The company is dedicated to empowering customers to live healthier lives by providing consumers direct access to their genetic information and digital access to affordable, personalized healthcare.
• The company is building the leading direct-to-consumer precision medicine platform that powers its genetics-driven therapeutics and research business.
• The company believes that it can revolutionize research through its premier database of genetic and phenotypic information provided by its millions of engaged customers.

Industry Context

The company operates in the competitive direct-to-consumer genetic testing and telehealth markets, facing challenges from both established players and new entrants. The company's focus on leveraging its genetic database for drug discovery and development positions it uniquely in the pharmaceutical industry.

Comparison to Industry Standards

• The company's revenue decline and net losses are concerning when compared to industry leaders in the genetic testing and telehealth sectors, such as Exact Sciences and Teladoc Health, which have shown more robust growth and profitability.
• The goodwill impairment charge is a significant negative indicator, suggesting that the company overpaid for the Lemonaid Health acquisition and is struggling to integrate it effectively.
• The company's reliance on a single supplier for microarrays and kits is a significant risk, unlike diversified supply chains of larger competitors.
• The company's customer acquisition costs are likely higher than industry averages, given the need for extensive marketing and promotional activities to drive kit sales.
• The company's research and development spending, while significant, needs to translate into tangible therapeutic product candidates to justify the investment.

Management Changes

Legal Proceedings

• Multiple class action claims have been filed against the company in federal and state court in California, as well as in other U.S. and international jurisdictions, as a result of the cyber security incident.

Related Party Transactions

• The company entered into a research services agreement with the Troper Wojcicki Foundation (TWF), a related party, with fees of $5.4 million payable over five years.
• GSK is considered a related party to the company.

Stakeholder Impact

• Shareholders are negatively impacted by the significant net loss, goodwill impairment, and potential delisting from Nasdaq.
• Employees may be affected by the ongoing restructuring and potential future cost-cutting measures.
• Customers may be concerned about the cyber security incident and the potential exposure of their personal information.
• Suppliers and creditors may be concerned about the company's financial stability and ability to meet its obligations.

Next Steps

• The company intends to monitor the closing bid price of its common stock during the compliance period(s) and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement, including initiating a reverse stock split.
• The company will continue to investigate and respond to the cyber security incident and related litigation.
• The company will continue to develop its therapeutic product candidates and seek new collaboration agreements.

Key Dates

Keywords

23andMe, genetics, genomics, telehealth, research, therapeutics, goodwill impairment, Nasdaq, cyber security, revenue, net loss, stock price